Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- Registration Number
- NCT04985825
- Lead Sponsor
- Pega-One S.A.S.
- Brief Summary
This study will evaluate the anti-tumor activity, safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of imgatuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) with enhanced antibody-dependent cellular cytotoxicity (ADCC) in patients with advanced cutaneous squamous cell carcinoma (CSCC). Quality of life of patients treated with imgatuzumab will also be assessed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Histologically confirmed diagnosis of CSCC
- CSCC of advanced stage
- Males or females at least 18 years of age at the time of consent
- Signed informed consent provided prior to any study procedures
- Ability to and willing to understand informed consent and comply with protocol requirements and procedures
- No more than two prior lines of systemic treatment for advanced disease
- Patients must have at least one lesion that is considered as measurable according to the Study Response Criteria
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate function of bone marrow, liver, kidneys
- Availability of tumor tissue sample (either an archival specimen or a fresh biopsy material) at Screening
Key
- Prior systemic treatment for advanced disease with any anti-EGFR agent
- Active central nervous system metastasis
- Systemic anti-cancer therapy within five half-lives or two weeks, whichever is shorter, prior to first dose of the study drug
- Persistent toxicities from previous systemic anti-neoplastic treatments
- Wide-field radiotherapy within four weeks, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within two weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
- Major surgery within four weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
- Active infection requiring therapy
- Concomitant use of systemic steroids at dose of >10 mg of prednisone or its equivalent per day
- Known or suspected allergy/hypersensitivity to the study drug or any component of the study drug, other monoclonal antibodies, premedication medicines
- Concurrent participation in another investigational therapeutic clinical trial
- Pregnant or breast-feeding females
- Mental or medical conditions that prevent the patient from giving informed consent or participating in the trial
- Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with the study participation or the study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for enrollment in this study
Note: Other protocol defined Inclusion/Exclusion criteria apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Imgatuzumab monotherapy Imgatuzumab -
- Primary Outcome Measures
Name Time Method Overall Response Rate (ORR) assessed by the Independent Central Review Committee (ICRC) according to the Study Response Criteria Up to 24 months Proportion of patients achieving Complete Response (CR) or Partial Response (PR) assessed by the ICRC according to the Study Response Criteria
- Secondary Outcome Measures
Name Time Method Disease Control Rate (DCR) assessed by the ICRC according to the Study Response Criteria Up to 24 months Proportion of patients achieving CR, PR or Stable Disease (SD) assessed by the ICRC according to the Study Response Criteria
ORR assessed by the investigator according to the Study Response Criteria Up to 24 months Proportion of patients achieving CR or PR assessed by the investigator according to the Study Response Criteria
DCR assessed by the investigator according to the Study Response Criteria Up to 24 months Proportion of patients achieving CR, PR or SD assessed by the investigator according to the Study Response Criteria
Progression-free Survival (PFS) assessed by the ICRC Up to 24 months Time from date of start of treatment to date of the first progression documented by the ICRC
Duration of Response (DoR) assessed by the ICRC Up to 24 months Time from date of first assessment of response (CR or PR) to date of the first progression documented by the ICRC
Duration of Stable Disease (DoSD) assessed by the ICRC Up to 24 months Time from date of first assessment of SD to date of the first progression documented by the ICRC
PFS assessed by the investigator Up to 24 months Time from date of start of treatment to date of the first progression documented by the investigator
DoR assessed by the investigator Up to 24 months Time from date of first assessment of response (CR or PR) to date of the first progression documented by the investigator
DoSD assessed by the investigator Up to 24 months Time from date of first assessment of SD to date of the first progression documented by the investigator
ORR assessed by the ICRC according to the immune Response Evaluation Criteria in Solid Tumors (iRECIST) Up to 24 months Proportion of patients achieving CR or PR assessed by the ICRC according to the iRECIST
DCR assessed by the investigator according to the iRECIST Up to 24 months Proportion of patients achieving CR, PR or SD assessed by the investigator according to the iRECIST
PFS assessed by the ICRC according to the iRECIST Up to 24 months Time from date of start of treatment to date of the first iRECIST progression documented by the ICRC
DCR assessed by the ICRC according to the iRECIST Up to 24 months Proportion of patients achieving CR, PR or SD assessed by the ICRC according to the iRECIST
DoR assessed by the ICRC according to the iRECIST Up to 24 months Time from date of first assessment of response (CR or PR) to date of the first iRECIST progression documented by the ICRC
Incidence of Adverse Events Up to 24 months Safety and tolerability profile assessed by Common Terminology Criteria for Adverse Events v5.0
ORR assessed by the investigator according to the iRECIST Up to 24 months Proportion of patients achieving CR or PR assessed by the investigator according to the iRECIST
DoR assessed by the investigator according to the iRECIST Up to 24 months Time from date of first assessment of response (CR or PR) to date of the first iRECIST progression documented by the investigator
DoSD assessed by the ICRC according to the iRECIST Up to 24 months Time from date of first assessment of SD to date of the first iRECIST progression documented by the ICRC
DoSD assessed by the investigator according to the iRECIST Up to 24 months Time from date of first assessment of SD to date of the first iRECIST progression documented by the investigator
Frequency of dose interruptions and reductions Up to 24 months Safety and tolerability profile assessed by frequency of dose interruptions and reductions
Duration of dose interruptions and reductions Up to 24 months Safety and tolerability profile assessed by duration of dose interruptions and reductions
Concentrations of imgatuzumab-reactive antibodies Up to 24 months Immunogenicity profile characterized by concentrations of imgatuzumab-reactive antibodies
Maximum observed concentration (C[max]) Up to 24 months Pharmacokinetic profile characterized by the maximum observed concentration (C\[max\]) of imgatuzumab
Area under the curve (AUC) Up to 24 months Pharmacokinetic profile characterized by the area under the curve (AUC) of imgatuzumab
Terminal half-life (t[1/2]) Up to 24 months Pharmacokinetic profile characterized by the terminal half-life (t\[1/2\]) of imgatuzumab
Time to maximum concentration (Tmax) Up to 24 months Pharmacokinetic profile characterized by the time to maximum concentration (Tmax) of imgatuzumab
Change in scores of patient-reported outcomes Up to 24 months Quality of life assessed by change in scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores are transformed linearly to a zero to 100 scale. A higher score on the functional scale and the global Health related Quality of Life indicates better functioning
PFS assessed by the investigator according to the iRECIST Up to 24 months Time from date of start of treatment to date of the first iRECIST progression documented by the investigator